NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

PDS Biotech’s PDS01ADC Delivers Impressive 78% Response Rate in Advanced Colorectal Cancer Trial

PDS Biotech drug PDS01ADC improved tumor shrinkage and survival in colorectal cancer trials, showing strong early results.

PDS Biotech’s PDS01ADC Delivers Impressive 78% Response Rate in Advanced Colorectal Cancer Trial
Credit: PDS Biotech
Already have an account? Sign in.
04/15/2026 · 11:16 AM
PDSB
/ Don’t stop at just one post.

Related↓

PDS Biotech Submits Protocol Amendment for Faster Cancer Drug Approval
01/09/2026 · 11:37 AM

PDS Biotech Submits Protocol Amendment for Faster Cancer Drug Approval

PDS Biotechnology updates Phase 3 trial protocol with FDA to potentially speed up approval of PDS0101 for HPV-related head and neck cancer treatment.

/ Subscriber only
/ Read more

Feed↓

Jazz Buys Rare Epilepsy Drug Company for Up to $1.32 Billion
08/10/2026 · 10:08 AM

Jazz Buys Rare Epilepsy Drug Company for Up to $1.32 Billion

Jazz Pharmaceuticals acquires Actio Biosciences for up to $1.32 billion, adding experimental drug ABS-1230 for rare KCNT1 epilepsy with no approved treatments.

/ Subscriber only
GameStop Weighs Dropping $56 Billion eBay Bid in Favor of Partnership
Featured/ 08/10/2026 · 9:56 AM

GameStop Weighs Dropping $56 Billion eBay Bid in Favor of Partnership

GameStop CEO Ryan Cohen may withdraw the $56 billion eBay takeover bid and pursue a partnership instead, using its 1,600 U.S. stores for collectibles.

/ Subscriber only
Intel Shares Drop as Chipmaker Raises $15 Billion to Fuel AI Expansion
08/10/2026 · 9:43 AM

Intel Shares Drop as Chipmaker Raises $15 Billion to Fuel AI Expansion

Intel cashes in on its stock rally with a $15 billion share sale aimed at boosting production capacity for surging AI demand.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe